StockWire X
Get Free Alerts
StockWire X

Syntara Pauses Scar Trial Recruitment After Skin Irritation Reports [VIDEO]

Video thumbnail
Syntara Ltd
Company Hub
Market Impact
4/10

Syntara has paused recruitment in its SNT-9465 Phase 1b scar study after reports of mild to moderate skin irritation, and will decide this quarter whether the study restarts or ends.

By Josua Ferreira -

Key Takeaways

  • Syntara has paused recruitment in its SNT-9465 Phase 1b scar study after reports of mild to moderate skin irritation in some patients.
  • The company will review unblinded data from completed and ongoing patients, and expects to finish that review this quarter.
  • After the review, Syntara will either restart recruitment or end the study.
  • The study had recently grown from 20 to 30 participants, with first results expected in the first three months of 2027.
  • Amsulostat, the lead drug, is still moving ahead in myelofibrosis, with a Phase 2b trial of roughly 100 patients supported by FDA feedback.
This is a special feature video produced for our partner.
Topic Hubs
Biotech & Health Biotechnology Healthcare Life Sciences Pharmaceutical Research
Most Popular
Categories

You May Also Like

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

  • Breaking ASX announcements delivered within minutes
  • Alerts delivered with expert analysis
  • Optional text alert for subscribers
  • No spam policy, unsubscribe any time
News
ASX Stock News
ASX Videos
Trending Topics▾
Capital MarketsRenewable EnergyMedical ImagingPortfolio ManagementASX 200ForexInflationInterest RatesAll OrdinariesAll Hub Pages
Analysis
Education
Free Alerts

About the Publisher

StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.

Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.

Use of Technology

We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.

While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.

Feedback and Accuracy

We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Editorial Standards

Disclaimer

StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).

StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.

Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.

StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.

Disclosure

StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.

If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Disclaimer